Model-based rational design of an oncolytic virus with improved therapeutic potential
Fabrice Le Bœuf(Ottawa Hospital), John C. Bell(Ottawa Hospital), Cory Batenchuk(Ottawa Hospital), Harold Atkins(University of Ottawa), Markus Vähä‐Koskela(University of Helsinki), Julie A. Cox(Ottawa Hospital), Chantal G. Lemay(University of Ottawa), Mads Kærn(University of Ottawa), David F. Stojdl(Ottawa Regional Cancer Foundation), Dominic G. Roy(University of Ottawa), Sophie Breton(Université de Montréal), Hesham Abdelbary(University of Ottawa), Theresa Falls(Ottawa Hospital), Girija Waghray(University of Ottawa), Jean‐Simon Diallo(University of Ottawa)
Cited by 44
Related Papers
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
|Cancer Cell|2003|850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
|Nature Medicine|2000|816
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
|The Lancet Oncology|2008|522
A FLUORINATED GLUCOSE ANALOG, 2-FLUORO-2-DEOXY-D-GLUCOSE (F-18)
|Journal of Computer Assisted Tomography|1980|503
Glucose Metabolic Rate Kinetic Model Parameter Determination in Humans: The Lumped Constants and Rate Constants for [ <sup>18</sup> F]Fluorodeoxyglucose and [ <sup>11</sup> C]Deoxyglucose
|Journal of Cerebral Blood Flow & Metabolism|1985|419